UPDATE-(NASDAQ: NRSN) shares are moving up again more than 31% today on news of positive preliminary results from Alzheimer’s Biomarker Study.

Shares are $3.64 on more than 33 million in volume and closing in on 92,000 trades one hour after the open.

NeuroSense Therapeutics Reports Positive Preliminary Results from Novel Alzheimer’s Biomarker Study USA – English 


CAMBRIDGE, Mass., June 30, 2022 /PRNewswire/ — NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) (“NeuroSense”), a company developing treatments for severe neurodegenerative diseases, today announced results from a biomarker study conducted to evaluate the potential of CogniC, NeuroSense’s combination drug for the treatment of Alzheimer’s disease (AD).


Signup today for free and be the first to get notified of breaking news.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.


Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

Add New Playlist